Boston Scientific initiates new Farapulse trial, expects FDA approval in 2024 – MassDevice

Boston Scientific announced that it initiated the AVANT GUARD clinical trial to evaluate its Farapulse pulsed-field ablation (PFA) system.

Do you trust this headline?

Based on recent headline ratings, 91% of this readership currently trusts the local media, which has an average score of 74% regionally and is currently trending positive.


Media Trust Score91%